4.7 Article

Clinical effectiveness of zoster vaccine live in kidney transplant recipients immunized prior to transplantation: a retrospective single- centre cohort study

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 29, Issue 7, Pages 911-917

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2023.02.014

Keywords

Attenuated; Herpes zoster; Kidney transplantation; Varicella zoster virus; Zoster vaccine live

Ask authors/readers for more resources

This study found that vaccinating kidney transplant recipients against herpes zoster before transplantation effectively prevents the disease and has a significant protective effect. Patients who were not vaccinated had a higher risk of developing herpes zoster.
Objectives: Kidney transplant (KT) recipients have an increased risk of herpes zoster (HZ) and its com-plications. Although recombinant zoster vaccine is favoured over zoster vaccine live (ZVL), ZVL is also recommended to prevent HZ for KT candidates. We aimed to evaluate the clinical effectiveness of ZVL in KT recipients immunized before transplantation. Methods: Adult patients who received kidney transplantation from January 2014 to December 2018 were enrolled. Patients were observed until HZ occurrence, death, loss of allograft, loss to follow-up, or 5 years after transplantation. The inverse probability of the treatment-weighted Cox proportional hazard model was used to compare the incidence of HZ after transplantation between vaccinated and unvaccinated patients. Results: A total of 84 vaccinated and 340 unvaccinated patients were included. The median age was higher in the vaccinated group (57 vs. 54 years, p 0.003). Grafts from deceased donors were more frequently transplanted in the unvaccinated group (16.7% vs. 51.8%, p < 0.001). Five-year cumulative HZ incidence was 11.9%, which translated to 26.27 (95% CI, 19.33-34.95) per 1000 person-years. The inci-dence in the vaccinated and unvaccinated groups was 3.9% and 13.7%, respectively. After adjustment, vaccination showed significant protective effectiveness against HZ (adjusted hazard ratio, 0.18, 95% CI, 0.05-0.60). In addition, all four cases of disseminated zoster occurred in the unvaccinated group. Discussion: Our study, the first on the clinical effectiveness of zoster vaccines for KT recipients, suggests that ZVL before transplantation effectively prevents HZ. Si-Ho Kim, Clin Microbiol Infect 2023;29:911 & COPY; 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available